Viral Inactivation Buffer Inactivir SDI STANDARD
Inactivir® SDI has the same non-guanidine inactivation system as Inactivir® SD, but also contains buffer components that inactivate nucleotide degrading enzymes including RNAses. Inactivir® SDI also includes an additional chaotrope along with the non-guanidine inactivation system. This provides excellent stability for samples and allows the sample to be used directly in silica-based purification systems.
The LSG Viral Inactivation Buffer Inactivir®, developed in collaboration with the University of Bedfordshire, has been formulated to provide a buffer that will inactivate viruses such as Covid-19, seasonal influenza, SARS, MERS and Ebola.
The use of samples collected in Inactivir® will increase laboratory throughput by reducing the requirement for Category 2+/3 handling of potentially pathogenic samples, increasing the speed and ease of testing. This formulation has been validated by Public Health England.
KEY BENEFITS:
• Any viral particles within the patients samples contained within the tube are inactivated and rendered non-pathogenic.
• Samples do not need to be maintained at +4°C, removing the need for a cold chain in handling.
• The buffer components are widely compatible with current RNA extraction protocols and can be used without disruption to current processing protocols.
• The buffer acts as a stabiliser since the formulation will destroy the enzymes and proteins (including RNAses) which are responsible for the degradation of the RNA/DNA.
• Does not contain PCR inhibitors.
The LSG Viral Inactivation Buffer Inactivir®, developed in collaboration with the University of Bedfordshire, has been formulated to provide a buffer that will inactivate viruses such as Covid-19, seasonal influenza, SARS, MERS and Ebola.
The use of samples collected in Inactivir® will increase laboratory throughput by reducing the requirement for Category 2+/3 handling of potentially pathogenic samples, increasing the speed and ease of testing. This formulation has been validated by Public Health England.
KEY BENEFITS:
• Any viral particles within the patients samples contained within the tube are inactivated and rendered non-pathogenic.
• Samples do not need to be maintained at +4°C, removing the need for a cold chain in handling.
• The buffer components are widely compatible with current RNA extraction protocols and can be used without disruption to current processing protocols.
• The buffer acts as a stabiliser since the formulation will destroy the enzymes and proteins (including RNAses) which are responsible for the degradation of the RNA/DNA.
• Does not contain PCR inhibitors.
| Supplier | Amerigo Scientific |
|---|---|
| Product # | VIB-005C-E-G |
| Pricing | 50mL; 10mL; 1mL, Inquire |